Literature DB >> 8796867

Transporting therapeutics across the blood-brain barrier.

N J Abbott1, I A Romero.   

Abstract

In 1996, we are half-way through the Decade of the Brain, yet we still have few effective treatments for major disorders of the central nervous system. These include affective disorders, epilepsy, neurodegenerative disorders, brain tumours, infections and HIV encephalopathy; sufferers far outnumber the morbidity of cancer or heart disease. Increased understanding of the pharmacology of the brain and its blood supply, and methods for rational drug design, are leading to potential new drug therapies based on highly specific actions on particular target sites, such as neurotransmitter receptors and uptake systems. These methods are capable of reducing the side effects that are common with more general treatments. However, all these treatments and potential treatments meet a formidable obstacle--the blood-brain barrier. In this article, we review the properties of this barrier that complicate drug delivery to the brain, and some of the most hopeful strategies for overcoming or bypassing the barrier in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8796867     DOI: 10.1016/1357-4310(96)88720-x

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  97 in total

1.  Evaluation of an in vitro coculture model for the blood-brain barrier: comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources.

Authors:  J L Scism; D A Laska; J W Horn; J L Gimple; S E Pratt; R L Shepard; A H Dantzig; S A Wrighton
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

Review 2.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

3.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 4.  New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 Mar-Apr

Review 5.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

Review 6.  Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.

Authors:  S R Barnum
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

7.  Cerebral edema following photodynamic therapy using endogenous and exogenous photosensitizers in normal brain.

Authors:  Marlon S Mathews; David Chighvinadze; H Michael Gach; Francisco A Uzal; Steen J Madsen; Henry Hirschberg
Journal:  Lasers Surg Med       Date:  2011-11       Impact factor: 4.025

Review 8.  Dynamics of CNS barriers: evolution, differentiation, and modulation.

Authors:  N Joan Abbott
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

9.  Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells.

Authors:  Rachel C Brown; Andrew P Morris; Roger G O'Neil
Journal:  Brain Res       Date:  2006-12-12       Impact factor: 3.252

Review 10.  Astrocyte-endothelial interactions and blood-brain barrier permeability.

Authors:  N Joan Abbott
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.